Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of DNA damage repair pathway utilization in high-grade serous ovarian cancers yields rational therapeutic approaches

12 Sept 2024

Abstract excerpt

While poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have improved the prognosis of ovarian high-grade serous carcinoma (HGSC) tumors that are homologous recombination (HR) deficient (HRD), new therapeutic strategies are needed for tumors that are HR proficient (HRP) because they demonstrate greater resistance to current treatments and thus have poorer clinical outcomes. Additionally, clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39270525
DOI: 10.1016/j.tranon.2024.102119

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of DNA damage repair pathway utilization in high-grade serous ovarian cancers yields rational therapeutic approachesPMID 39270525Read ↗

Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian CarcinomasSemantic proximity Read ↗

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall SurvivalSemantic proximity Read ↗

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune systemSemantic proximity Read ↗

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell linesSemantic proximity Read ↗

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer CellsSemantic proximity Read ↗

Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis groupSemantic proximity Read ↗

Therapeutic targeting and patient selection for cancers with homologous recombination defects.Semantic proximity Read ↗

The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignanciesSemantic proximity Read ↗

Biology-driven therapy advances in high-grade serous ovarian cancerSemantic proximity Read ↗

Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.Semantic proximity Read ↗

Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.